Novel therapeutic targets for multiple myeloma

Future Oncology

Volumn 6, Issue 3, 2010, Pages 407-418

  Mahindra, Anuj ^a   Cirstea, Diana ^b   Raje, Noopur ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aurora kinase inhibitor; Cyclin dependent kinase inhibitor; Histone deacetylase inhibitor; HSP90 inhibitor; MTOR inhibitor; Myeloma; Novel agent; Pomalidomide

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; BORTEZOMIB; CARFILZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; DNA METHYLTRANSFERASE; DOXORUBICIN; ENZASTAURIN; EVEROLIMUS; FTI 5777; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; IMETELSTAT; LENALIDOMIDE; MELPHALAN; NSC 639966; PERIFOSINE; PLACEBO; POMALIDOMIDE; PREDNISONE; ROSCOVITINE; SALINOSPORAMIDE A; SILTUXIMAB; SORAFENIB; STAT PROTEIN; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER RISK; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA;

EID: 77949429892     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.2     Document Type: Review

References (96)

1. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111(5), 2521-2526 (2008).
2. Rajkumar SV, Rosinol L, Hussein M et al.: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26(13), 2171-2177 (2008).
3. San Miguel JF, Schlag R, Khuageva NK et al.: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
4. Richardson PG, Barlogie B, Berenson J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003).
5. Richardson PG, Sonneveld P, Schuster MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
6. Dimopoulos MA, Chen C, Spencer A et al.: Long-term follow-up on overall survival from the MM-009 and MM-010 Phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11), 2147-2152 (2009).
7. Weber DM, Chen C, Niesvizky R et al.: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007).
8. Orlowski RZ, Nagler A, Sonneveld P et al.: Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25(25), 3892-3901 (2007).
9. Dimopoulos M, Spencer A, Attal M et al.: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
10. Rajkumar SV, Jacobus S, Callander N et al.: A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 110(11), 74 (2007).
11. Rajkumar SV, Hayman SR, Lacy MQ et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dexamethasone) for newly diagnosed myeloma. Blood 106(13), 4050-4053 (2005).
12. Harousseau JL, Attal M, Leleu X et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM Phase II study. Haematologica 91(11), 1498-1505 (2006).
13. Palumbo A, Bringhen S, Caravita T et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513), 825-831 (2006).
14. Palumbo A, Falco P, Corradini P et al.: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA -Italian Multiple Myeloma Network. J. Clin. Oncol. 25(28), 4459-4465 (2007).
15. Mateos MV, Hernandez JM, Hernandez MT et al.: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter Phase I/2 study. Blood 108(7), 2165-2172 (2006).
16. Richardson P, Lonial S, Jakubowiak A et al.: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II Study. ASH Annual Meeting Abstracts 112(11), 92 (2008).
17. Richardson P, Jagannath S, Jakubowiak A et al.: Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a Phase II Study. Blood 112(11), 614-615 (2008).
18. Singhal S, Mehta J, Desikan R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565-1571 (1999).
19. Rajkumar SV, Hayman S, Gertz MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20(21), 4319-4323 (2002).
20. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21(1), 16-19 (2003).
21. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4), 314-322 (2004).
22. Mitsiades N, Mitsiades CS, Poulaki V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12), 4525-4530 (2002).
23. Gupta D, Treon SP, Shima Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12), 1950-1961 (2001).
24. Lacy MQ, Hayman SR, Gertz MA et al.: Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
25. Jagannath S, Vij R, Stewart K et al.: Final results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASCO Meeting Abstracts 27(15 Suppl.), 8504 (2009).
26. Vij R, Wang M, Orlowski R et al.: PX-171-1004, a multicenter Phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. ASCO Meeting Abstracts 27(15 Suppl.), 8537 (2009).
27. Niesvizky R, Bensinger W, Vallone M, Gutierrez A, Kunkel L: PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (Lenalidomide) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results. J. Clin. Oncol. 27(15 Suppl.), 8541 (2009).
28. Chauhan D, Catley L, Li G et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8(5), 407-419 (2005).
29. Piva R, Ruggeri B, Williams M et al.: CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5), 2765-2775 (2008).
30. Hofmeister CC, Richardson P, Zimmerman T et al.: Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). ASCO Meeting Abstracts 27(15 Suppl.), 8505 (2009).
31. Chauhan D, Singh A, Brahmandam M et al.: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111(3), 1654-1664 (2008).
32. Hideshima T, Catley L, Raje N et al.: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br. J. Haematol. 138(6), 783-791 (2007).
33. Tai YT, Podar K, Catley L et al.: Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3́-kinase/AKT signaling. Cancer Res. 63(18), 5850-5858 (2003).
34. Hsu J, Shi Y, Krajewski S et al.: The AKT kinase is activated in multiple myeloma tumor cells. Blood 98(9), 2853-2855 (2001).
35. Hideshima T, Catley L, Yasui H et al.: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107(10), 4053-4062 (2006).
36. Gajate C, Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109(2), 711-719 (2007).
37. Richardson P, Wolf J, Jakubowiak A et al.: Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. ASH Annual Meeting Abstracts 112(11), 870 (2008).
38. Jakubowiak A, Richardson P, Zimmerman TM et al.: Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 112(11), 3691 (2008).
39. Podar K, Raab MS, Zhang J et al.: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 109(4), 1669-1677 (2007).
40. Hideshima T, Chauhan D, Richardson P, Anderson KC: Identification and validation of novel therapeutic targets for multiple myeloma. J. Clin. Oncol. 23(26), 6345-6350 (2005).
41. Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A: Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J. Biol. Chem. 277(18), 15712-15720 (2002).
42. Shi Y, Gera J, Hu L et al.: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62(17), 5027-5034 (2002).
43. Hu L, Shi Y, Hsu JH, Gera J, van Ness B, Lichtenstein A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101(8), 3126-3135 (2003).
44. Raje N, Kumar S, Hideshima T et al.: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13), 4188-4193 (2004).
45. Stromberg T, Dimberg A, Hammarberg A et al.: Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103(8), 3138-3147 (2004).
46. Yan H, Frost P, Shi Y et al.: Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 66(4), 2305-2313 (2006).
47. Frost P, Moatamed F, Hoang B et al.: In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 104(13), 4181-4187 (2004).
48. Easton JB, Houghton PJ: mTOR and cancer therapy. Oncogene 25(48), 6436-6446 (2006).
49. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671-688 (2006).
50. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12(1), 9-22 (2007).
51. Farag SS, Zhang S, Jansak BS et al.: Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk. Res. 33(11), 1475-1480 (2009).
52. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13), 1932-1940 (2007).
53. Sun SY, Rosenberg LM, Wang X et al.: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65(16), 7052-7058 (2005).
54. Cirstea D, Hideshima T, Pozzi S et al.: Combination of Nab-rapamycin and perifosine induces synergistic cytotoxicity and antitumor activity via autophagy and apoptosis in multiple myeloma (MM). ASH Annual Meeting Abstracts 112(11), 3663 (2008).
55. Ghobrial IM, Munshi N, Schlossman R et al.: Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 112(11), 3696 (2008).
56. Mitsiades CS, Mitsiades NS, McMullan CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101(2), 540-545 (2004).
57. Catley L, Weisberg E, Tai YT et al.: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102(7), 2615-2622 (2003).
58. O'Connor OA, Heaney ML, Schwartz L et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24(1), 166-173 (2006).
59. Richardson P, Mitsiades C, Colson K et al.: Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma 49(3), 502-507 (2008).
60. Wolf JL, Siegel D, Matous J et al.: A Phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. ASH Annual Meeting Abstracts 112(11), 2774 (2008).
61. Ottmann OG, Spencer A, Prince HM et al.: Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts 112(11), 958 (2008).
62. Weber D, Badros AZ, Jagannath S et al.: Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. ASH Annual Meeting Abstracts 112(11), 871 (2008).
63. Siegel D, Weber D, Mitsiades CS et al.: A Phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 112(11), 3705 (2008).
64. Siegel DD, Sezer O, San Miguel JF et al.: A Phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and i. v. bortezomib in patients with relapsed multiple myeloma. ASH Annual Meeting Abstracts 112(11), 2781 (2008).
65. Deleu S, Lemaire M, Arts J et al.: Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 69(13), 5307-5311 (2009).
66. Badros AZ, Philip S, Niesvizk R et al.: Phase I trial of vorinostat plus bortezomib (BORT) in relapsed/refractory multiple myeloma (MM) patients (PTS). ASCO Meeting Abstracts 26(15 Suppl.), 8548 (2008).
67. Harrison SJ, Quach H, Yuen K et al.: High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a Phase I/II clinical trial. ASH Annual Meeting Abstracts 112(11), 3698 (2008).
68. Spencer A, Taylor K, Lonial S et al.: Panobinostat plus lenalidomide and dexamethasone Phase I trial in multiple myeloma (MM). ASCO Meeting Abstracts 27(15 Suppl.), 8542 (2009).
69. Mitsiades N, Mitsiades CS, Poulaki V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99(22), 14374-14379 (2002).
70. Chanan-Khan AA, Munshi NC, Hussein MA et al.: Results of a Phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 112(11), 3688 (2008).
71. Richardson P, Chanan-Khan AA, Lonial S et al.: A multicenter Phase I clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 108(11), 406 (2006).
72. Abramson JS, Chen W, Juszczynski P et al.: The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br. J. Haematol. 144(3), 358-366 (2009).
73. Cerchietti LC, Lopes EC, Yang SN et al.: A purine scaffold HSP90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 15(12), 1369-1376 (2009).
74. Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23(26), 6333-6338 (2005).
75. Baughn LB, Di Liberto M, Wu K et al.: A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66(15), 7661-7667 (2006).
76. Raje N, Kumar S, Hideshima T et al.: Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106(3), 1042-1047 (2005).
77. Raje N, Hideshima T, Mukherjee S et al.: Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23(5), 961-970 (2009).
78. Puthier D, Bataille R, Amiot M: IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. 29(12), 3945-3950 (1999).
79. Puthier D, Derenne S, Barille S et al.: Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br. J. Haematol. 107(2), 392-395 (1999).
80. Cirstea D, Hideshima T, Pozzi S et al.: RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and independent survival mechanisms. ASH Annual Meeting Abstracts 112(11), 2759 (2008).
81. Santo L, Vallet S, Hideshima T et al.: AT7519, a novel small molecule multi-cyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3b. ASH Annual Meeting Abstracts 112(11), 251 (2008).
82. Dutta-Simmons J, Zhang Y, Gorgun G et al.: Aurora kinase A is a target of Wnt/b-catenin involved in multiple myeloma disease progression. Blood 114(13), 2699-2708 (2009).
83. Evans RP, Naber C, Steffler T et al.: The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br. J. Haematol. 140(3), 295-302 (2008).
84. Hose D, Reme T, Meissner T et al.: Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18), 4331-4340 (2009).
85. Negri JM, McMillin DW, Delmore J et al.: In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br. J. Haematol. 147(5), 672-676 (2009).
86. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD: IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144(11), 4226-4230 (1990).
87. Voorhees PM, Chen Q, Kuhn DJ et al.: Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13(21), 6469-6478 (2007).
88. Tai YT, Dillon M, Song W et al.: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4), 1329-1337 (2008).
89. Neri P, Kumar S, Fulciniti MT et al.: Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 13(19), 5903-5909 (2007).
90. Tai YT, Li XF, Breitkreutz I et al.: Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 66(13), 6675-6682 (2006).
91. Shammas MA, Koley H, Bertheau RC et al.: Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22(7), 1410-1418 (2008).
92. Bezieau S, Devilder MC, Avet-Loiseau H et al.: High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 18(3), 212-224 (2001).
93. Alsina M, Fonseca R, Wilson EF et al.: Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9), 3271-3277 (2004).
94. Yanamandra N, Colaco NM, Parquet NA et al.: Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res. 12(2), 591-599 (2006).
95. Lonial S, Francis D, Karanes C et al.: A Phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/ refractory multiple myeloma. ASH Annual Meeting Abstracts 112(11), 3706 (2008).
96. Srkalovic G, Hussein M, Bolejack V, Hoering A, Zonder J, Barlogie B: A Phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). ASCO Meeting Abstracts 27(15 Suppl.), E19517 (2009).